Atara Biotherapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Atara Biotherapeutics yıllık ortalama 5% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 7.7% annual. Gelirler yılda ortalama 47.7% oranında büyüyor .

Anahtar bilgiler

5.0%

Kazanç büyüme oranı

23.5%

EPS büyüme oranı

Biotechs Sektör Büyümesi	-14.6%
Gelir büyüme oranı	47.7%
Özkaynak getirisi	n/a
Net Marj	-290.2%
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Atara Biotherapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

DB:AT20 Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	62	-181	41	0
31 Mar 24	35	-233	46	0
31 Dec 23	9	-276	50	0
30 Sep 23	5	-290	49	0
30 Jun 23	7	-305	56	0
31 Mar 23	57	-215	61	0
31 Dec 22	64	-228	68	0
30 Sep 22	71	-247	80	0
30 Jun 22	72	-248	81	0
31 Mar 22	24	-350	82	0
31 Dec 21	20	-340	79	0
30 Sep 21	13	-328	73	245
30 Jun 21	7	-318	68	245
31 Mar 21	4	-311	65	245
31 Dec 20	0	-307	64	0
30 Sep 20	0	-304	66	62
30 Jun 20	0	-301	71	115
31 Mar 20	0	-298	77	167
31 Dec 19	0	-291	80	216
30 Sep 19	0	-292	81	204
30 Jun 19	0	-279	79	194
31 Mar 19	0	-256	75	175
31 Dec 18	0	-231	70	167
30 Sep 18	0	-186	61	130
30 Jun 18	0	-159	55	107
31 Mar 18	0	-135	46	92
31 Dec 17	0	-119	40	81
30 Sep 17	0	-102	35	70
30 Jun 17	0	-97	31	68
31 Mar 17	0	-88	28	63
31 Dec 16	0	-79	25	57
30 Sep 16	0	-82	25	59
30 Jun 16	0	-69	22	49
31 Mar 16	0	-65	19	47
31 Dec 15	0	-57	17	42
30 Sep 15	0	-46	17	30
30 Jun 15	0	-41	14	27
31 Mar 15	0	-30	12	18
31 Dec 14	0	-28	13	15
30 Sep 14	0	-21	8	13
30 Jun 14	0	-18	7	10
31 Mar 14	0	-15	7	7

Kaliteli Kazançlar: AT20 şu anda kârlı değil.

Büyüyen Kar Marjı: AT20 şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: AT20 kârlı değildir, ancak son 5 yılda zararlarını yılda 5% oranında azaltmıştır.

Büyüme Hızlandırma: AT20 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: AT20 kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( -18.2% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: AT20 'un yükümlülükleri varlıklarından fazla olduğundan Özsermaye Getirisi'ni hesaplamak zordur.

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/09/14 17:47
Gün Sonu Hisse Fiyatı	2024/06/18 00:00
Kazançlar	2024/06/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Atara Biotherapeutics, Inc. 14 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
John Newman	Canaccord Genuity
Yigal Nochomovitz	Citigroup Inc
Jonathan Miller	Evercore ISI

Atara Biotherapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Atara Biotherapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

First quarter 2024 earnings released: US$0.23 loss per share (vs US$0.72 loss in 1Q 2023)

Full year 2023 earnings released: US$2.61 loss per share (vs US$2.24 loss in FY 2022)

Third quarter 2023 earnings released: US$0.66 loss per share (vs US$0.82 loss in 3Q 2022)

Atara Biotherapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Full year 2022 earnings released: US$2.24 loss per share (vs US$3.63 loss in FY 2021)

Recent updates

Atara Biotherapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Atara Biotherapeutics, Inc. Appoints Eric Hyllengren as Chief Operating Officer

Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $36 million.

Atara Biotherapeutics, Inc. Announces CEO Changes, Effective September 9, 2024

Atara Biotherapeutics Announces U.S. Fda Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-Cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

New major risk - Financial position

Atara Biotherapeutics Submits Tabelecleucel (Tab-cel) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA

First quarter 2024 earnings released: US$0.23 loss per share (vs US$0.72 loss in 1Q 2023)

Atara Biotherapeutics, Inc., Annual General Meeting, Jun 10, 2024

Full year 2023 earnings released: US$2.61 loss per share (vs US$2.24 loss in FY 2022)

Atara Biotherapeutics, Inc. Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis

Atara Biotherapeutics, Inc. and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel®? Data in The Lancet Oncology

Atara Biotherapeutics, Inc. has announced a Derivatives Offering in the amount of $15 million.

Atara Biotherapeutics, Inc. Announces Termination of Manher (Aj) Joshi as Executive Vice President, Chief Medical Officer, Effective as of February 2, 2024

Atara Biotherapeutics, Inc. Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting

Independent Director recently bought €95k worth of stock

New minor risk - Market cap size

Atara Biotherapeutics, Inc. Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis

Atara Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Financial position

Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Third quarter 2023 earnings released: US$0.66 loss per share (vs US$0.82 loss in 3Q 2022)

Atara Biotherapeutics, Inc. Announces Plans to Submit Tab-cel® BLA in Second Quarter 2024 Following FDA Agreement on Comparability

New major risk - Revenue and earnings growth

Atara Biotherapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New major risk - Financial position

Atara Biotherapeutics, Inc. Announces Resignation of Beth Seidenberg from the Board of Directors

Insufficient new directors

President recently sold €56k worth of stock

Atara Biotherapeutics, Inc. Announces Executive Changes

Full year 2022 earnings released: US$2.24 loss per share (vs US$3.63 loss in FY 2021)

Pierre Fabre and Atara Biotherapeutics Announce the Transfer of the European Commission Marketing Authorization for EBVALLO(TM)

Atara Biotherapeutics, Inc. to Report Q4, 2022 Results on Feb 08, 2023

Atara Biotherapeutics Announces Changes to Its Board of Directors

Atara Biotherapeutics, Inc. Appoints Carol Gallagher as Chair of the Board of Directors

Atara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (Allele) of Tab-Cel(R) At the 64Th American Society of Hematology (Ash) Annual Meeting

Third quarter 2022 earnings released: US$0.82 loss per share (vs US$0.91 loss in 3Q 2021)

Atara Biotherapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Atara Biotherapeutics, Inc. Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022

CHMP Recommends Approval of Atara Biotherapeutics, Inc. Ebvallo (Tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease

Atara Biotherapeutics, Inc. to Terminate Kristin Yarema as Senior Vice President and Chief Commercial Officer, Effective as of November 15, 2022

Atara Biotherapeutics, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Atara Biotherapeutics, Inc. Announces Completion of ATA188 Phase 2 EMBOLD Study Interim Analysis in Patients with Progressive MS

Atara Biotherapeutics Announces First Clinical Data from Ongoing Tab-cel® European Multicenter Expanded Access Program (EAP) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and Update on Tab-cel EMA Regulatory Progress

Atara Biotherapeutics Provides Update on Strategic Collaboration with Bayer

Atara and MSK Expects to Provide A Phase 1 Data Update for Ata2271 in Second Half 2022

Atara Biotherapeutics, Inc. Names Charlene Banard as Chief Technical Officer

Atara Biotherapeutics, Inc. Provides Update on ATA2271 Autologous CAR T Trial

Atara Biotherapeutics, Inc. to Report Fiscal Year 2021 Results on Feb 28, 2022

FUJIFILM Diosynth Biotechnologies California, Inc. entered into an asset purchase agreement to acquire T-Cell Operations and Manufacturing Facility in Thousand Oaks, California from Atara Biotherapeutics, Inc. (NasdaqGS:ATRA) for $100 million.

Atara Biotherapeutics, Inc. Lauds the Second High Impact Study This Month Solidifying EBV as the Primary Driver of the Development of MS

Atara Biotherapeutics, Inc. to Complete the Biologics License Application for Patients with EBV+ PTLD in Second Quarter of 2022

Atara Biotherapeutics Announces Positive Results from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 63rd American Society of Hematology (ASH) Annual Meeting

Atara Biotherapeutics, Inc. Announces New Preclinical and Preliminary Clinical Results for ATA2271 at ESMO Immuno-Oncology Congress 2021

Atara Biotherapeutics, Inc. Announces That the Marketing Authorization Application for Tabelecleucel (Tab-Cel®) Has Been Fully Validated by the European Medicines Agency

European Medicines Agency Grants Atara Biotherapeutics Accelerated Assessment of Tab-Cel® for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (Ptld)

High number of new directors

Atara Biotherapeutics Announces Operational Progress on Tabelecleucel (Tab-Cel®) for Post-Transplant Lymphoproliferative Disease (PTLD)

SVP & Chief Commercial Officer recently bought €413k worth of stock

Atara Biotherapeutics Presents Positive Tab-Cel Long-Term Overall Survival Data for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant at ATC 2021 Virtual Connect

Atara Biotherapeutics Presents New Long-Term Overall Survival Data from A Combined Analysis of Phase 2 Tab-Cel® Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease At the Ebmt 2021 Annual Meeting

Atara Biotherapeutics, Inc. Reports Operational Progress

New 90-day low: €13.90

Atara Biotherapeutics, Inc. to Report Q4, 2020 Results on Mar 01, 2021

Atara Biotherapeutics Presents Key Data for Advancing the Development of Tab-cel® and ATA188 at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience

Atara Biotherapeutics Provides Regulatory Update for Tab-Cel(R) for Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Atara Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $174.999792 million.

Atara Biotherapeutics Presents First Preclinical Evaluation of ATA3219 at the 62 American Society of Hematology Annual Meeting

Bayer and Atara Biotherapeutics Enter Strategic Collaboration for Mesothelin-Targeted CAR T-cell Therapies for Solid Tumors